LENALIDOMIDE + Acalabrutinib + OBINUTUZUMAB

1 treatment and condition followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

LENALIDOMIDE + Acalabrutinib + OBINUTUZUMAB
Treatment and conditionWhere it standsTrials
LENALIDOMIDE + Acalabrutinib + OBINUTUZUMAB for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1